---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Pharmacokinetics"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Pharmacokinetics. Topics: Absorption, dose proportionality, accumulation, and steady state in healthy participants; Physicochemical properties, permeability, and tissue distribution; Elimination half-life as stated by the manufacturer and a narrative review; Hepatic clearance, metabolites, and deuteration; 2 further topics. 6 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Absorption, dose proportionality, accumulation, and steady state in healthy participants

> “ESK‐001 was rapidly absorbed with systemic exposures generally increasing dose‐proportionally across all cohorts.”
> “The mean terminal half‐life ranged from 8 to 13 h with no to minimal accumulation of ESK‐001 following q.d. doses and ~2‐fold accumulation following Q12 doses.”
> “Following both single (≤100 mg) and multiple (≤60 mg q.d. and ≤40 mg Q12) dose administration, ESK‐001 was rapidly absorbed into the systemic circulation and afterward eliminated in an approximately monoexponential manner with less than 1% renal excretion.”
> “The systemic exposure of ESK‐001 showed linear dose‐dependent PK characteristics across the dose range, with steady state achieved by 3–5 days.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-2.1.2.6.3-2"></a>

### Physicochemical properties, permeability, and tissue distribution

> “ESK‐001 was designed to deliver best‐in‐class pharmacokinetics (PK), including rapid absorption, low PK variability, high permeability with no efflux, and good penetration into relevant tissues.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

> “Molecular weight <500 g/mol.”
> “Low polar surface area.”

Source: [Ucpinar et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_3_aad_poster_2024.pdf)

> “Envu is highly permeable with low efflux resulting in high and rapid systemic absorption and favorable tissue distribution in vivo.”
> “These properties result in its highly predictable, linear PK profile in humans with low variability.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.2.6.3-3"></a>

### Elimination half-life as stated by the manufacturer and a narrative review

> “In addition, envu has a desirable half-life in humans of approximately 8 to 12 hours and we have not observed any concerns for drug-drug interactions with other therapies.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

> “Envudeucitinib demonstrated a favorable pharmacokinetic profile characterized by rapid absorption, an elimination half-life of approximately 8 h, a dose-proportional increase in exposure, minimal renal clearance, and low interindividual variability”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

<a id="topic-2.1.2.6.3-4"></a>

### Hepatic clearance, metabolites, and deuteration

> “Envudeucitinib is primarily cleared through hepatic metabolism”
> “Studies evaluating absorption, distribution, metabolism, and excretion of envudeucitinib in healthy volunteers identified one major and seven minor metabolites (data on file).”
> “The major metabolite is pharmacologically inactive with no significant off-target effects; minor metabolites contribute minimally to the overall pharmacologic activity of envudeucitinib (data on file).”
> “Envudeucitinib includes a deuterated methyl triazole moiety that may enhance its metabolic stability by reducing cytochrome P450 1A2 (CYP1A2)-mediated demethylation, mitigating potential metabolite-driven off-target effects, and maximizing the pharmacodynamic response.”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

<a id="topic-2.1.2.6.3-5"></a>

### Linear kinetics in participants with psoriasis

> “Envudeucitinib demonstrated consistent, dose-proportional linear kinetics with low interindividual variability in patients with psoriasis”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

<a id="topic-2.1.2.6.3-6"></a>

### Peak and steady-state trough concentrations in the STRIDE open-label extension

> “On day 1 post-dose, mean plasma concentrations reached approximately 200 ng/mL around 2 hours after drug administration.”
> “At week 16, mean steady-state Ctrough levels were approximately 54 ng/mL for the 40-mg QD dose and 170 ng/mL for the 40-mg BID dose.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
